Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Papadopoulos

Showing results (171-180 of 288) with videos related to

Pageof 29
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|October 1, 1986
Cloning, characterization, expression, and chromosomal localization of a human ferritin heavy-chain geneM W Hentze, S Keim, P Papadopoulos, et al.
Marine Pollution Bulletin|August 11, 2023
Pollution status determination using trace metals and organic contaminants of the water column in coastal areas of the Red Sea and the Gulf of Aqaba: A baseline assessmentE Tzempelikou, C Parinos, C Zeri, et al.
Expert Opinion on Drug Safety|September 7, 2023
COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan®) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT)Stylianos Kandarakis, Alexandros P Papadopoulos, Georgios Roussopoulos, et al.
Neuro-Oncology Advances|April 30, 2026
Phase 1 LITESPARK-001 study of belzutifan in participants with advanced solid tumors: Results of the glioblastoma expansion cohortRoy E Strowd, Macarena de la Fuente, Todd M Bauer, et al.
Cancer|October 19, 2011
A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphomaBruce D Cheson, Nancy L Bartlett, Julie M Vose, et al.
American Journal of Hypertension|October 16, 2004
Insulin receptor number is reduced in healthy offspring of patients with essential hypertensionThomas A Makris, Ioannis Paizis, Panagiota G Krespi, et al.
Leukemia & Lymphoma|October 11, 2014
Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphomaKyriakos P Papadopoulos, Coumaran Egile, Rodrigo Ruiz-Soto, et al.
American Journal of Hypertension|August 16, 2015
Apelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood PressureCharalampos I Liakos, Elias A Sanidas, Despoina N Perrea, et al.
Marine Pollution Bulletin|December 21, 2023
Organic contaminants levels, distribution and risk assessment in Jeddah marine coastal zone sedimentsI Hatzianestis, C Parinos, S Chourdaki, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|August 12, 2020
Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors)Charalampos I Liakos, Dimitrios P Papadopoulos, Elias A Sanidas, et al.
Pageof 29

Showing results (171-180 of 288) with videos related to

Sort By:
Pageof 29
Proceedings of the National Academy of Sciences of the United States of America|October 1, 1986
Cloning, characterization, expression, and chromosomal localization of a human ferritin heavy-chain geneM W Hentze, S Keim, P Papadopoulos, et al.
Marine Pollution Bulletin|August 11, 2023
Pollution status determination using trace metals and organic contaminants of the water column in coastal areas of the Red Sea and the Gulf of Aqaba: A baseline assessmentE Tzempelikou, C Parinos, C Zeri, et al.
Expert Opinion on Drug Safety|September 7, 2023
COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan®) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT)Stylianos Kandarakis, Alexandros P Papadopoulos, Georgios Roussopoulos, et al.
Neuro-Oncology Advances|April 30, 2026
Phase 1 LITESPARK-001 study of belzutifan in participants with advanced solid tumors: Results of the glioblastoma expansion cohortRoy E Strowd, Macarena de la Fuente, Todd M Bauer, et al.
Cancer|October 19, 2011
A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphomaBruce D Cheson, Nancy L Bartlett, Julie M Vose, et al.
American Journal of Hypertension|October 16, 2004
Insulin receptor number is reduced in healthy offspring of patients with essential hypertensionThomas A Makris, Ioannis Paizis, Panagiota G Krespi, et al.
Leukemia & Lymphoma|October 11, 2014
Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphomaKyriakos P Papadopoulos, Coumaran Egile, Rodrigo Ruiz-Soto, et al.
American Journal of Hypertension|August 16, 2015
Apelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood PressureCharalampos I Liakos, Elias A Sanidas, Despoina N Perrea, et al.
Marine Pollution Bulletin|December 21, 2023
Organic contaminants levels, distribution and risk assessment in Jeddah marine coastal zone sedimentsI Hatzianestis, C Parinos, S Chourdaki, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|August 12, 2020
Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors)Charalampos I Liakos, Dimitrios P Papadopoulos, Elias A Sanidas, et al.
Pageof 29